Business Wire

WA-KYMETA

8.6.2021 15:02:04 CEST | Business Wire | Press release

Share
Kymeta Broadens Network Offerings for Government and Military Through Strategic Partnership with Comtech

Kymeta (kymetacorp.com ), the communications company making mobile global, announced today a strategic technology partnership with Comtech EF Data Corp. (comtechefdata.com ), a leading provider of satellite communication equipment. The agreement enables Kymeta to broaden its network of offerings for the Kymeta™ u8 terminal through interoperability with Comtech’s SLM-5650B modem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005043/en/

The pairing of the u8 antenna and Comtech modem using the Open Antenna to Modem Interface Protocol (OpenAMIP), an industry-wide open-source standard for antenna-router integration, allows for seamless integration and automatic operation through the use of both Low Density Parity Check (“LDPC”) waveforms and STANAG 4486 Edition 3, Annex E (EBEM) waveforms.

The Comtech SLM-5650B is a U.S. Army Forces Strategic Command (ARSTRAT) Wideband Global SATCOM certified modem for critical commercial backhaul, as well as government and military applications. It is fully compliant with MIL-STD-188-165A/B, complies with and supports FIPS 140-2 certified encryption.

Kymeta u8 terminals, antennas, and ODUs are easy to set up and acquire service within minutes of installation. The u8 is also available in a transportable configuration called the u8 GO, which is ideal for rapid deployments. The u8 GO enables safe transport with a hardened case for protection and provides a built-in car mount to support easy communications on the pause (COTP) and on the move (COTM).

“The integration of the u8 antenna with the Comtech modem allows users to upgrade to a SATCOM-on-the-move (SOTM) capability while utilizing existing modem and hub architecture,” said Neville Meijers, Kymeta Chief Strategy and Marketing Officer. “The ability to leverage existing network hardware while adding the SOTM capability will rapidly enhance unit capabilities. The low SWaP-C2 of the u8 terminal also makes it a perfect choice for upgrading legacy COTM terminals.”

“Comtech is very excited to expand our solution set and capabilities offered to our government and military user base,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp. “The engineering, development, and testing of the mobility protocols between our widely fielded SLM-5650B satellite modem and Kymeta’s state-of-the-art u8 antenna expands the range of missions we can support and further demonstrates the flexibility and long-term developmental support our government and military users expect from our products.”

Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, public safety, and commercial customers. Kymeta’s products and services have been field deployed for over three years and received an overwhelmingly positive response from the industry. Kymeta’s new products and services offer a breakthrough in performance, ease of use, and affordability, and Kymeta anticipates that these solutions will further enhance its position in both commercial and government markets, further increasing its lead over competitive offerings.

This strategic technology partnership with Comtech follows a series of recently announced relationships to further expand Kymeta solutions and trainings for government and defense agencies and its Global TRANSEC Secure Network , which is available coverage in the U.S., Middle East, and Europe. Visit www.kymetacorp.com to learn more.

About Kymeta

Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.

Kymeta is a privately held company based in Redmond, Washington.

For more information, visit kymetacorp.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/kymetacorp/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye